104 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
N-Arylsulfonyl-a-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity.
Boehringer Ingelheim Pharmaceuticals
Discovery and synthesis of cyclohexenyl derivatives as modulators of CC chemokine receptor 2 activity.
Bristol-Myers Squibb
Synthesis and biological evaluation of spirocyclic antagonists of CCR2 (chemokine CC receptor subtype 2).
Westf£Lische Wilhelms-Universit£T M£Nster
Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5.
Bristol-Myers Squibb
When structure-affinity relationships meet structure-kinetics relationships: 3-((Inden-1-yl)amino)-1-isopropyl-cyclopentane-1-carboxamides as CCR2 antagonists.
Leiden University
Design and synthesis of novel small molecule CCR2 antagonists: evaluation of 4-aminopiperidine derivatives.
TBA
The discovery and SAR of cyclopenta[b]furans as inhibitors of CCR2.
Janssen Research and Development
Alkylsulfone-containing trisubstituted cyclohexanes as potent and bioavailable chemokine receptor 2 (CCR2) antagonists.
Bristol-Myers Squibb
Discovery and SAR of 5-aminooctahydrocyclopentapyrrole-3a-carboxamides as potent CCR2 antagonists.
Janssen Research and Development
Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors.
Amgen
Targeting CCR2 Receptor To Treat Inflammation Diseases and Disorders.
Therachem Research Medilab (India)
A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists.
Janssen Research and Development
Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists.
Janssen Research and Development
Validated QSAR analysis of some diaryl substituted pyrazoles as CCR2 inhibitors by various linear and nonlinear multivariate chemometrics methods.
Tehran University of Medical Sciences
Discovery of a 4-Azetidinyl-1-thiazoyl-cyclohexane CCR2 Antagonist as a Development Candidate.
TBA
Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis.
Bristol-Myers Squibb
Benzimidazoles as benzamide replacements within cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.
Bristol-Myers Squibb
The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity.
Astrazeneca
Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.
TBA
Discovery of an orally-bioavailable CC Chemokine Receptor 2 antagonist derived from an acyclic diaminoalcohol backbone.
Bristol-Myers Squibb
Substituted dipiperidine alcohols as potent CCR2 antagonists.
Johnson & Johnson Pharmaceutical Research and Development
Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series.
Deltagen Research Laboratories (Former Combichem)
Conformational studies of 3-amino-1-alkyl-cyclopentane carboxamide CCR2 antagonists leading to new spirocyclic antagonists.
Merck Research Laboratories
Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists.
TBA
Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
Ono Pharmaceutical
Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.
Novartis Institutes For Biomedical Research
Inhibition of protein-protein association by small molecules: approaches and progress.
Pfizer
Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist.
TBA
Synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamide-derived antagonists of CC chemokine receptor 2 (CCR2).
Bristol-Myers Squibb
The discovery of novel cyclohexylamide CCR2 antagonists.
Johnson & Johnson Pharmaceutical Research and Development
CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood.
Glaxosmithkline
Design and synthesis of a library of chemokine antagonists.
Novartis Institutes of Biomedical Research
Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.
Johnson & Johnson Pharmaceutical Research and Development
Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.
Johnson & Johnson Pharmaceutical Research and Development
Discovery of ((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxy-tetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(5-(trifluoromethyl)pyridazin-3-yl)piperazin-1-yl)methanone, PF-4254196, a CCR2 antagonist with an improved cardiovascular profile.
Pfizer
Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.
Telik
Design and synthesis of novel CCR2 antagonists: investigation of non-aryl/heteroaryl binding motifs.
Pfizer
Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist.
Incyte
Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
Incyte
gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.
Bristol-Myers Squibb
Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
Genzyme
Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.
Yangji Chemicals
Novel sulfone-containing di- and trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.
Bristol-Myers Squibb
Design, synthesis, and structure-activity relationship of novel CCR2 antagonists.
Merck Research Laboratories
Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.
Bristol-Myers Squibb
Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.
Roche Palo Alto
Synthesis and structure-activity relationship of 7-azaindole piperidine derivatives as CCR2 antagonists.
Johnson & Johnson Pharmaceutical Research and Development
Synthesis and evaluation of cis-3,4-disubstituted piperidines as potent CC chemokine receptor 2 (CCR2) antagonists.
Bristol-Myers Squibb
Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers.
Université
QSAR studies on CCR2 antagonists with chiral sensitive hologram descriptors.
National Institute of Pharmaceutical Education and Research (NIPER)
Probing the structural and topological requirements for CCR2 antagonism: holographic QSAR for indolopiperidine derivatives.
National Institute of Pharmaceutical Education and Research (NIPER)
Potent heteroarylpiperidine and carboxyphenylpiperidine 1-alkyl-cyclopentane carboxamide CCR2 antagonists.
Merck Research Laboratories
Synthesis, structure-activity relationship and in vivo antiinflammatory efficacy of substituted dipiperidines as CCR2 antagonists.
Johnson & Johnson Pharmaceutical Research and Development
Synthesis and biological evaluation of phenyl piperidine derivatives as CCR2 antagonists.
Johnson & Johnson Pharmaceutical Research and Development
Capped diaminopropionamide-glycine dipeptides are inhibitors of CC chemokine receptor 2 (CCR2).
Bristol-Myers Squibb
Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma.
Johnson & Johnson Pharmaceutical Research and Development
3-Amino-1-alkyl-cyclopentane carboxamides as small molecule antagonists of the human and murine CC chemokine receptor 2.
Merck Research Laboratories
Discovery of 3-piperidinyl-1-cyclopentanecarboxamide as a novel scaffold for highly potent CC chemokine receptor 2 antagonists.
Merck Research Laboratories
Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment.
Sichuan University
Alpha-aminothiazole-gamma-aminobutanoic amides as potent, small molecule CCR2 receptor antagonists.
Merck Research Laboratories
Diaryl substituted pyrazoles as potent CCR2 receptor antagonists.
Merck Research Laboratories
Cyclic tailor-made amino acids in the design of modern pharmaceuticals.
Nanjing Forestry University
Novel, orally bioavailable gamma-aminoamide CC chemokine receptor 2 (CCR2) antagonists.
Merck Research Laboratories
4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties.
Merck Research Laboratories
Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.
Merck Research Laboratories
Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
Takeda Pharmaceutical
Identification of chemokine receptor CCR4 antagonist.
Bristol-Myers Squibb Pharmaceutical Research Institute
Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.
Pharmaceutical Research Institute
Small molecule antagonists of the CCR2b receptor. Part 2: Discovery process and initial structure-activity relationships of diamine derivatives.
Deltagen Research Laboratories
Small molecule inhibitors of the CCR2b receptor. Part 1: Discovery and optimization of homopiperazine derivatives.
Institute For Bio-Medical Research
BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate.
Bristol Myers Squibb
N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor.
Astrazeneca
CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach.
Glaxosmithkline
Design and Characterization of an Intracellular Covalent Ligand for CC Chemokine Receptor 2.
Leiden Academic Centre For Drug Research
Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2.
Bristol Myers Squibb
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.
Merck Research Laboratories
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.
Merck Research Laboratories
Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists.
Glaxosmithkline
Design, synthesis, and discovery of a novel CCR1 antagonist.
Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.
Merck Research Laboratories
CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound.
Smithkline Beecham Pharmaceuticals
Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.
Takeda Chemical Industries
Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2.
Leiden University
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Terns Pharmaceuticals
Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672.
Bristol-Myers Squibb
Synthesis and Pharmacological Evaluation of Triazolopyrimidinone Derivatives as Noncompetitive, Intracellular Antagonists for CC Chemokine Receptors 2 and 5.
Leiden University
Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions.
Shanghai Jiao Tong University
Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.
Glaxosmithkline
Discovery and synthesis of 6,7,8,9-tetrahydro-5H-pyrido[4,3-c]azepin-5-one-based novel chemotype CCR2 antagonists via scaffold hopping strategy.
Shanghai Institute of Materia Medica
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists.
Gsk Pharmaceuticals R & D